Early careers Early careers At Boehringer Ingelheim, we know how important it is to lay the right foundations in your career and build on them with care and support.
NexGard COMBO for cats EMA marketing authorization NexGard COMBO for cats EMA marketing authorization Boehringer Ingelheim received marketing authorization from the EMA (European Medicine Agency) for its NexGard® COMBO topical solution for cats.
Celebrating Women in Technology Celebrating Women in Technology We want to elevate women in technology: empower them, affirm their potential and enable them to soar to new heights
Phase II results cognitive impairment schizophrenia Phase II results cognitive impairment schizophrenia Presented at ECNP Congress, Phase II trial results demonstrated improvement in cognition with BI 425809 in schizophrenia patients
DiaTEC new purification technology Ingelvac CircoFLEX DiaTEC new purification technology Ingelvac CircoFLEX Boehringer Ingelheim introduces DiaTEC, a new and proprietary purification technology for Ingelvac CircoFLEX®
Advance study vaccinating increased milk production Advance study vaccinating increased milk production [New ADVANCE study shows vaccinating with Bovela® results in increased milk production
Aservo EquiHaler wins Pharmapack Award 2021 Aservo EquiHaler wins Pharmapack Award 2021 Boehringer Ingelheim’s Aservo® EquiHaler® is recognized in the 2021 Pharmapack Awards
global-top-employer global-top-employer For the first time, Boehringer Ingelheim receives the award as a Global Top Employer as well as individual awards in 27 countries.
FRONTLINE® becomes Brand of the Year 2021-22 FRONTLINE® becomes Brand of the Year 2021-22 FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards
Sabine Reinig Sabine Reinig For Sabine, who leads Boehringer Ingelheim’s global people strategy, continuous development is the essence of a successful career. Clear aspirations and openness to new opportunities are her key ingredients.
PREVEXXION® RN: Marek’s disease vaccine available in EU UK PREVEXXION® RN: Marek’s disease vaccine available in EU UK Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
Boehringer Ingelheim attends WVPAC 2019 Boehringer Ingelheim attends WVPAC 2019 Boehringer Ingelheim attends and showcases its leading vaccines and services at 21st World Veterinary Poultry Association Congress
Classical Swine Fever live vaccine approved in China Classical Swine Fever live vaccine approved in China Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
Agreement-to-acquire-NBE-Therapeutics Agreement-to-acquire-NBE-Therapeutics Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
expanded-collaboration-MD-Anderson expanded-collaboration-MD-Anderson The continued collaboration aims to accelerate the development of KRAS and TRAILR2 compounds in lung cancer
Really Digital, Mr Hach! Really Digital, Mr Hach! The Head of User Experience and SCRUM at Boehringer Ingelheim’s digital lab BI X offers a glimpse into his work and motivation.
Purevax range now available in 0.5 ml presentation Purevax range now available in 0.5 ml presentation Boehringer Ingelheim announces reduced volume 0.5 ml Purevax vaccines for cats, more convenient vaccination experience combined with same efficacy
Jean-Michel Boers Appointed to PhRMA Board of Directors Jean-Michel Boers Appointed to PhRMA Board of Directors Jean-Michel Boers Appointed to PhRMA Board of Directors
New digital Tx collab with Click New digital Tx collab with Click New digital therapy collaboration with Click Tx
GioTag Final Data GioTag Final Data Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
Research ruminant animal health well-being Research ruminant animal health well-being Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research